EMVision Medical Devices (ASX:EMV) said five of the six validation trial sites for its emu bedside brain scanner are actively enrolling and scanning patients, according to a Wednesday Australian bourse filing.
Recruitment is currently ongoing at its third US-based site in New York. The final sixth site for the validation trial recently cleared its local institutional review board.
The validation trial has an estimated enrollment period of six to 12 months, and up to 300 suspected stroke patients will be enrolled across four sites in the US and two sites in Australia.
The firm also secured ethics approval to begin scanning patients with suspected stroke or traumatic brain injury at Princess Alexandra Hospital in Brisbane, Queensland, and John Hunter Hospital in Newcastle, New South Wales. It will use the results for continued device innovation, algorithm enhancement, and data to support indication expansion.
Its shares rose 3% in recent trading on Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。